Kidney, A031704

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Immunotherapy, A151804

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Esophageal, MK-7902-014

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), S1925

Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with CLL/SLL

Breast, TOL2506A

Ovarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA)

Breast, Pfizer-C4891001

VERITAC-2- Open-Label Trial of ARV-471 (PF-07850327) vs. Fulvestrant in PTS W/ ER-Positive, HER2-Negative Advanced Breast Cancer w/ Disease Progression After Prior Endocrine Rx For Advanced Disease

Breast, NRG-BR007

DEBRA-De-escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18

Breast, CELC-G-301

Viktoria-1 Gedatolisib in Combination with Palbociclib and Fulvestrant Compared to SOC in Previously Treated Pts with HR-Positive, HER2 Negative Advanced Breast Cancer

Breast, A011801

CompassHer2 Residual Disease (RD): Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

February's "Cancer News from HOA" on 93Q with Amy Robbins: Dr. Gajra discusses the latest in immunotherapy

Dr. Gajra talks about the latest in Immunotherapy when it comes to cancer treatment in February’s interview below.

Pages